Dementia and cognitive impairment pattern: Its association with ε4 allele of apolipoprotein E gene;Demencia y patrón de deterioro cognitivo: Asociación con el alelo ε4 del gen de la apolipoproteína E

Revista de Neurologia

Volumn 38, Issue 9, 2004, Pages 801-807

  Rosich Estragó, Marcel ^a,b   Figuera Terre L ^c   Mulet Perez B ^d   Arrufat Cardus M T ^a   Pascual San Emeterio, A ^a   Arbeloa Rigau, I ^a   Labad Alquezar A ^a,b   Vilella Cuadrada, E ^a,b  

^a IISPV   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^c Inst de Recerca en Cie de la Salut   (Spain)

^d Institut Pere Mata   (Spain)

Author keywords

Age related cognitive decline; Alzheimer disease; Apolipoprotein E; Dementia; Mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; ONSET AGE;

EID: 3142784478     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3809.2003336     Document Type: Article

References (44)

1. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 2000; 54 (Suppl 5): S4-9.
2. Alberca R, López-Pousa S. Enfermedad de Alzheimer y otras demencias. Madrid: Médica Panamericana; 2002.
3. Manubens JM. Epidemiología del deterioro cognitivo ligero. Neurología 2002; 17: 1-9.
4. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405.
5. Pérez-Tur J. La genética y la enfermedad de Alzheimer. Rev Neurol 2000; 30: 161-9.
6. Martorell L, Virgos C, Valero J, Coll G, Figuera L, Joven J, et al. Schizophrenic women with the APOE ε4 allele have a worse prognosis than those without it. Mol Psych 2001; 6: 307-10.
7. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 4725-7.
8. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small JW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
9. Blacker D, Haines JL, Rodes L. Terwedow H, Go RCP, Harrell LE, et al. APOE-4 and age at onset of Alzheimer's disease. Neurology 1997; 48: 139-47.
10. Meyer M, Tschanz J, Norton M, Welsh-Bohmer K, Steffens D, Wyse B, et al. APOE genotype predicts when -not wether- one is predisposed to develop Alzheimer disease. Nat Genet 1998; 19: 321-2.
11. López OL, López-Pousa S, Kamboh MI, Adroer R, Oliva R, Lozano-Gallego M, et al. Apolipoprotein E polymorphism in Alzheimer's disease: a comparative study of two research populations from Spain and the United States. Eur Neurol 1998; 39: 229-33.
12. Myers RH, Schaefer EJ, Wilson PWF, D'Agostino R, Ordovas JM, Espino A, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham Study. Neurology 1996; 46: 673-7.
13. Farrer LA, Cupples A, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 1997; 278: 1349-56.
14. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, et al. Protective effect of apolipoprotein E type 2 for late-onset Alzheimer's disease. Nat Genet 1994; 7: 180-4.
15. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al. The apolipoprotein E ε4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002; 59: 1154-60.
16. Dik MG, Jonker C, Bouter LM, Geerlings MI, Van Kamp GJ, Deeg DJ. APOE-epsilon 4 is associated with memory decline in cognitively impaired elderly. Neurology 2000; 54: 1492-7.
17. Haan M, Shemanski L, Jagust WL, Manolio TA, Kuller L. The role of APOE ε4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999; 282: 40-6.
18. Bartrés-Faz D, Junqué C, López-Alomar A, Valveny N, Moral P, Casamayor R, et al. Neuropsychological and genetic differences between age-associated memory impairment and mild cognitive impairment entities. J Am Geriatr Soc 2001; 49: 985-90.
19. Gómez-Tortosa E, Irizarry MC, Ingraham AO, Hyman BT. Dementia with Lewy bodies. J Am Geriatr Soc 1998; 46: 1449-58.
20. Del Ser T. Demencia con cuerpos de Lewy. Formas puras y mixtas. Rev Neurol 2002; 35: 761-5.
21. Verpillat P, Camuzat A, Hennequin D, Thomas-Anterion C, Puel M, Belliard S, et al. Apolipoprotein E gene in frontotemporal dementia: an asociation study and meta-analysis. Eur J Hum Genet 2002; 10: 399-405.
22. Ingelson M, Fabre SF, Liliius L, Anderson C, Viitanem M, Almkvist O, et al. Increased risk for frontotemporal dementia through interaction between tau polymorphism and apolipoprotein E epsilon 4. Neuroreport 2001; 12: 905-6.
23. Geschwind D, Karrim J, Nelson SF, Miller B. The apolipoprotein E epsilon4 allele is not significant risk factor for frontotemporal dementia. Ann Neurol 1998; 44: 134-8.
24. Skoog I, Hesse C, Aevarsson O, Landahl S, Wahlström J, Fredman P, et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998; 64: 37-43.
25. Chapman J, Wang N, Treves TA, Korczyn AD, Bornstein NM. ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and alzheimer's dementia. Stroke 1998; 29: 1401-4.
26. Slooter AJ, Tang MX, Van Duijin CM, Stem Y, Ott A, Bell K, et al. Apolipoprotein E epsilon 4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997; 277: 818-21.
27. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, et al. Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologica 2001; 39: 1150-7.
28. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, et al. Evidence-based dementia practice. Oxford: Blackwell Science; 2002.
29. Hixon J, Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and clevage with Hhal. J Lipid Res 1990; 31: 545-8.
30. Farrer LA. Intercontinental epidemiology of Alzheimer disease: a global approach to bad gene hunting. JAMA 2001; 285: 796-8.
31. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002; 287: 329-36.
32. Hebert LE, Scherr PA, McCann JJ, Becket LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol 2001; 153: 132-6.
33. Rena L, Shen Y, Yang LB, Lue LF, Finch C, Rogers J. Estrogen enhances uptake of amyloid β-protein by microglia derived from the human cortex. J Neurochem 2000; 75: 1447-54.
34. Sano M. Understanding the role of estrogen on cognition and dementia. J Neural Transm 2000; 59: 223-9.
35. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 1997; 143: 313-8.
36. Lai F, Kammann E, Rebeck GW, Anderson A, Chen Y, Nixon RA. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 1999; 53: 331-6.
37. Patel BN, Seltzer GB, WU HS, Chupf N. Effect of menopause on cognitive performance in women with Down syndrome. Neuroreport 2001; 12: 2659-62.
38. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kohmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
39. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster N. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001; 58: 411-6.
40. Tsuang D, Larson EB, Bowen J, McCormick W, Teri L, Nochlin D, et al. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Arch Neurol 1999; 56: 1489-945.
41. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-53.
42. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utiliy of the apolipoprotein E genotype in the diagnosis of Alzheimer's Disease. N Engl J Med 1998; 338: 506-11.
43. Robles A, Del Ser T, Alom J, Peña-Casanova J. Propuesta de criterios para el diagnóstico del deterioro cognitivo ligero, la demencia y la enfermedad de Alzheimer. Neurología 2002; 17: 17-32.
44. Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol Aging 1999; 14: 295-303.